Abstract 2672
Background
Vulvar cancer is a rare malignancy. Its occurrence in Japan is 1/6-1/10 of that in the Western countries. Population-based statisics for vulvar cancer has been missing in Japan. To examine trends in clinico-pathological characteristics of vulvar cancer in Japan.
Methods
This is a nationwide retrospective study examining consecutive cases of women with invasive vulvar cancer in Japan between 2001-2010 (n = 1,061). Temporal trends of demographics, tumor characteristics, and survival outcome were assessed with cohort-level analysis. The National Cancer Institute’s Surveillance, Epidemiology, and End Result Program served as the external validation (n = 10,154).
Results
The number of oldest-old women aged ≥80 years significantly increased from 18.0% to 30.6% (70.5% relative increase) over time. There was a stage-shift observed, and stage I disease decreased from 43.0% to 34.0% (21.0% relative decrease) whereas tumors with inguino-femoral nodal or distant metastasis increased from 23.2% to 35.6% (53.3% relative increase) during the study period (P < 0.05). The number of women who underwent surgical treatment decreased from 84.0% to 69.7% (17.0% relative decrease) whereas utilization of radiotherapy increased from 34.4% to 43.2% (25.7% relative increase) over time (P < 0.05). In the cohort-level analysis, the 5-year survival rates significantly decreased between 2001-2010 (P < 0.05): 66.9% to 51.0% for progression-free survival (23.7% relative decrease), 79.5% to 67.9% for cause-specific survival (14.6% relative decrease), and 74.9% to 62.3% for overall survival (16.9% relative decrease). In the patient-level analysis, oldest-old women were less likely to undergo surgical treatment and independently associated with decreased survival (all, P < 0.05). In the US cohort, the number of oldest-old women (25.2% to 27.8%) and the 5-year cause-specific survival rate (81.8% to 79.9%) stayed unchanged during the study period (all, P > 0.05).
Conclusions
Demographics and outcomes of vulvar cancer in Japan have significantly changed during the study period: Increasing oldest-old population and stage-shift to more metastatic disease resulted in cohort-level decrease in survival rates.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1694 - Pembrolizumab (pembro) Plus mFOLFOX or FOLFIRI in Patients With Metastatic Colorectal Cancer (mCRC): KEYNOTE-651 Cohorts B and D
Presenter: Richard Kim
Session: Poster Display session 2
Resources:
Abstract
908 - Romidepsin (FK228) Regulates the Expression of the Immune Checkpoint Ligand PD-L1 and Exerts Synergistic Anti-Tumor Activity with an Anti-PD-1 Antibody in Colon Cancer
Presenter: Hui Li
Session: Poster Display session 2
Resources:
Abstract
3127 - Prognostic significance of circulating regulatory T lymphocytes (Tregs) in patients with metastatic colorectal cancer (mCRC) under treatment with first line chemotherapy.
Presenter: Zafeiris Zafeiriou
Session: Poster Display session 2
Resources:
Abstract
5416 - The SAFFO study: Sex-related prognostic role And cut-oFf deFinition of monocyte-to-lymphocyte ratio (MLR) in metastatic colOrectal cancer
Presenter: Camilla Lisanti
Session: Poster Display session 2
Resources:
Abstract
2518 - SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumors of epithelial origin: analysis of the metastatic colorectal cancer patients in the dose escalation phase
Presenter: Marwan Fakih
Session: Poster Display session 2
Resources:
Abstract
4000 - Phase 1/2 study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer
Presenter: Niels Halama
Session: Poster Display session 2
Resources:
Abstract
2223 - Microsatellite Instability Status in Metastatic Colorectal Cancer and Effect of Immune Checkpoint Inhibitors on Survival in MSI-High Metastatic Colorectal Cancer
Presenter: Wataru Okamoto
Session: Poster Display session 2
Resources:
Abstract
2569 - Phase II trial of Trametinib (T) and Panitumumab (Pmab) in RAS/RAF wild type (wt) metastatic colorectal cancer (mCRC)
Presenter: Kanan Alshammari
Session: Poster Display session 2
Resources:
Abstract
5402 - Microsatellite instability and immunogenicity in colorectal cancer – do resident memory Tcells (Trm) play a role in colorectal cancer
Presenter: Wei Toh
Session: Poster Display session 2
Resources:
Abstract
5472 - Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevazicumab in patients with chemorefractory metastatic colorectal cancer (mCRC)
Presenter: Camilla Qvortrup
Session: Poster Display session 2
Resources:
Abstract